Fig. 5

ABR-238901 reverses established cardiac dysfunction and is a more efficient treatment compared to Dexamethasone. A–E Delayed ABR-238901 treatment starting from 12 h post LPS successfully rescues cardiac dysfunction during endotoxemia. A Experimental layout for B–D. B Repeated LVEF measurements and % LVEF change from treatment start to 24h post-LPS. C Absolute LVSV and % LVSV change from treatment start. D Absolute LVCO and % LVCO change from treatment start. E Experimental layout for F–H. F–H Comparison between treatment with ABR-238901 and Dexamethasone on cardiac function during endotoxemia. Following disease induction, the mice were treated either with 2 mg/kg Dexamethasone at 0h or with ABR-238901 at 0 and 6 h post-LPS. F–H LVEF, LVSV and LVCO over time and area under the curve. Statistical testing of echocardiographic parameters over time was performed by repeated-measures 2-way ANOVA with Fisher’s LSD Test. The P-values reflect the difference between treatment groups over time. The symbols reflect the difference between treatment groups at the respective time point. The statistical difference between two groups was tested with Student’s t-test. Differences between three groups were tested using 1-way ANOVA with Fisher’s LSD Test. Normality assessment was performed with Shapiro–Wilk test. *, ABR versus PBS; *P < 0.05, **P < 0.01, ***P < 0.001; †, ABR vs Dexa; † P < 0.05; PBS, Phosphate Buffered Saline; ABR, ABR-238901; Dexa, Dexamethasone; AUC, area under curve; LVEF, Left ventricular ejection fraction; LVSV, Left ventricular stroke volume; LVCO, Left ventricular cardiac output. Data is presented as mean ± SD. N = 4–5 per group